Article
Artificial intelligence-based prediction of claudin 18.2 expression and immune phenotype from routine histology to guide treatment decisions in patients with gastric cancer.
ESMO open - 1 Jul 2026
Kim H-D, Shin S, Hwang W, Shin J, Lee T, Hyung J, Park J, Pereira S, Ock C-Y, Puccini A, Carloni G, Park Y S, Ryu M-H
Abstract excerpt
BACKGROUND: First-line treatment of gastric cancer is evolving with the integration of immune checkpoint inhibitors (ICIs) and targeted agents, complicating biomarker stratification. Claudin 18.2 (CLDN18.2) is an established target for zolbetuximab; however, immunohistochemistry (IHC) is limited by tissue requirements, cost, and turnaround time. Artificial intelligence (AI) analysis of hematoxylin and eosin...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.